Colorectal cancer screening statistics routinely understate the true benefit of fecal occult blood testing — a methodological blind spot that may be quietly distorting public health decisions and individual participation rates. A large Swedish prospective cohort study now quantifies how much that understatement matters, and the answer has real implications for how screening programs should be evaluated.
Conducted in the Stockholm-Gotland region between 2008 and 2021, the study tracked yearly birth cohorts of individuals aged 60 to 69 — drawn from those born between 1938 and 1954 — who were randomly assigned to an invited study group (screened 2008–2012) or a control group (screened later or not at all). Using Poisson regression, researchers estimated colorectal cancer-specific mortality rate ratios after applying two critical statistical corrections: contamination bias (some control-group members had accessed screening outside the program) and nonadherence (some invited individuals never participated). Deaths from CRC diagnosed more than two years after cessation of screening were also separated from the primary outcome to tighten the causal window. After these adjustments, the estimated mortality reduction attributable to actual screening participation was substantially larger than the unadjusted intention-to-treat figures.
This finding matters beyond Sweden. Most published FOBT trial results report intention-to-treat estimates, which dilute apparent benefit by pooling adherent and non-adherent participants. The adjusted analysis methodology applied here — analogous to complier average causal effect approaches used in pharmaceutical trials — is rarely applied rigorously in cancer screening research. The study reinforces a growing consensus that FOBT's protective signal is real and meaningful when measured cleanly, but it also highlights a limitation inherent to observational cohort designs: residual confounding cannot be fully ruled out even with randomized group assignment, particularly if health-seeking behavior differs between adherers and non-adherers. As fecal immunochemical tests (FIT) increasingly replace guaiac FOBT, these methodological lessons remain directly applicable to ongoing screening program evaluation worldwide.